Boehringer Mannheim
This article was originally published in The Gray Sheet
Executive Summary
David Giddings named president of Boehringer Mannheim Corporation and Staffan Ek appointed president of the diabetes care business. Giddings will continue in his position as chief operating officer and will now "assume responsibility for the corporate affairs" of the Corange division. Before arriving at BMC in 1992, Giddings served as vice president and general manager of Eastman Kodak's printing and publishing division and clinical diagnostics division. Ek most recently served as head of international sales and marketing for the diabetes care unit, joining the company in 1992 after 20 years at Pharmacia. Giddings and Ek replace Andre de Bruin, who served as both president and CEO of Boehringer and president of Diabetes Care. de Bruin resigned July 1 to "pursue new business opportunities in the health care field"
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.